Abstract:PurposeHypodensity of pancreatic ductal adenocarcinoma (PDAC) during contrast-enhanced computed tomography (CECT) examination is common, but a minority of PDAC patients exhibit hyperdense images. The present study examined the clinical characteristics and protein landscape of PDAC with hyperdensity.Materials and MethodsA total of 844 pathologically confirmed PDAC patients who underwent CECT before surgery were included. During the parenchymal phase of CECT, patients were assigned to the hyperdense or hypodense group based on CT values. Clinical and CT characteristics for predicting relapse-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan–Meier method and Cox proportional hazards model. The expression of the tumor angiogenesis marker CD31 and stroma-related protein CTHRC1 were analyzed using immunohistochemistry (IHC) assay to evaluate differences between the two groups. Proteomics was performed to compare the possible mechanisms underlying the differential enhancement on CT scans.ResultsBased on CECT, 43 and 801 PDAC patients had hyperdense and hypodense lesions, respectively. All 43 patients presented a hyperdense lesion in the parenchymal phase. The mean CECT values of the hyperdense group were higher than the hypodense group (102.5 ± 17.4 and 53.7 ± 18.7, respectively, P< 0.001). The hyperdense group had a better prognosis than the hypodense group (median RFS, 19.97 vs. 12.34 months, P = 0.0176; median OS, 33.6 vs. 20.3 months, P = 0.047). Multivariate analysis showed that age, higher CA19-9 levels (> 300 U/ml), tumor stage, tumor differentiation, tumor CT density, and adjuvant chemotherapy were significant independent prognostic factors for OS. CD31 immunohistochemical staining showed that the hyperdense PDACs had a higher microvessel density than the hypodense group (P< 0.001). CTHRC1 expression was higher in the hypodense group (P = 0.019). Sixty-eight differentially expressed proteins were found using the tandem mass tag labeling-based quantification of the proteomes of PDAC tissue samples, and 7 proteins (POFUT1, PKP2, P0DOX4, ITPR1, HBG2, IGLC3, SAA2) were related to angiogenesis.ConclusionPatients who presented with a hyperdense mass on CECT had a higher microvessel density and better prognosis. Anti-angiogenic therapy may be suitable for these patients.

From clinic to mechanism: Proteomics-based assessment of angiogenesis in adrenal pheochromocytoma.

Predicting angiogenesis in adrenal pheochromocytoma: the role of modified parameters from contrast-enhanced CT

HIF1A transcriptional regulation of COX4I2 impacts angiogenesis in pheochromocytoma

COX4I2 is a Novel Biomarker of Blood Supply in Adrenal Tumors.

Molecular Cluster Mining of Adrenocortical Carcinoma Via Multi-Omics Data Analysis Aids Precise Clinical Therapy.

Adrenal pheochromocytoma impacts three main pathways: cysteine-methionine, pyrimidine, and tyrosine metabolism

Expression and Diagnostic Relevance of Heat Shock Protein 90 and Signal Transducer and Activator of Transcription 3 in Malignant Pheochromocytoma

Histopathological Analysis of Tumor Microenvironment and Angiogenesis in Pheochromocytoma

Relationship of Heparanase-1 and Cox-2 Expressions with Angiogenesis in Pheochromocytoma

Bioinformatic Analysis of Differentially Expressed Genes As Prognostic Markers in Pheochromocytoma and Paraganglioma Tumors.

Prognostic Prediction and Immunotherapy Response Analysis of the Fatty Acid Metabolism-Related Genes in Clear Cell Renal Cell Carcinoma

Heparanase-1 and Cyclooxygenase-2: Prognostic Indicators of Malignancy in Pheochromocytomas

Expression of Cyclooxygenase-2 in malignant pheochromocytomas and the relationship between Cyclooxygenase-2 and vascular endothelial growth factor,microvessel density

Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma

ScRNA-seq of Diverse Pheochromocytoma Patients Reveals Distinct Microenvironment Characteristics and Supports an Informative Molecular Classification System

Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 Patients.

Expression and significance of VEGF and NSE in benign and malignant pheochromocytoma

The Expression and Significance of Tumor Marker in Malignant Pheochromocytoma

Expression of vascular endothelial growth factor(VEGF) in malignant pheochromocytomas and the relationship between VEGF and microvessel density

Diagnostic Value of Immunohistochemical Markers in Tissue Microarray of Pheochromocytoma

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape